Free Newsletter
China suspends vax doses following minor's death
China's Sinovac Biotech says that health officials in Beijing suspended the use of 83 doses of the inactivated hepatitis A vaccine Healive after a minor died two days after being vaccinated. Sinovac noted that out of the 19,850 doses distributed from the same lot of vaccines, no other adverse events had been recorded.
On November 29, regulators inspected Sinovac's manufacturing facility and reviewed its inspections and sales process without finding any irregularities, according to the company. Sinovac says it will continue to cooperate with the authorities and plans a follow-up report.
- check out the Sinovac release
- read RTTNews coverage
Related Article:
Sinovac to mass produce bird flu vaccine (2006)
Comments
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities


SHARE
WITH: